Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
Very exciting trial. DNX-2401 is an oncolytic virus that had some success alone with GBMs - they reportedly even had 3 complete responses (out of 37 patients). At last report, these 3 patients are still alive and have no evidence of disease 3.2, 2, and 1.75 years after treatment - See details at: http://www.onclive.com/conference-coverage/sno-2014/Oncolytic-Virus-Shows-Early-Promise-in-Glioma#sthash.CQvVJ6Pr.dpuf This used to be called Delta-24-RGD-4C.
Keytruda is a checkpoint inhibitor which has the potential to reverse the immune inhibition that GBMs have. Combining these 2 treatments might make a major breakthrough. When the oncolytic virus kills a tumor cell, the Keytruda might allow the body's immune system to recognize and learn from the dead gbm cells and to kill the living GBM cells.
Posted on: 10/04/2015
Click HERE to return to brain tumor news headlines